tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

IntelGenx reports Q4 EPS (1c) vs (1c) last year

Reports Q4 revenue $426,000 vs $173,000 last year. “We successfully executed against key strategic priorities in 2023, the most important of which was to lay the groundwork for our product pipeline and services portfolio to start generating significant revenues in 2024,” commented Dwight Gorham, IntelGenx’s CEO. “To that end, we expect that our commercial partner for RIZAFILM(R)1, Gensco Pharma, will be launching the product in the United States in Q2-2024, an anticipated inflection point for our business.”

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Disclaimer & DisclosureReport an Issue

1